Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

 
 

Zoetis (NYSE:ZTS)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$221.44 (27.0% Upside)

About Zoetis

Zoetis logoZoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/11/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$225.00 ➝ $230.00
9/18/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$200.00 ➝ $210.00
8/27/2024Stifel NicolausReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/14/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$195.00 ➝ $210.00
8/12/2024BTIG ResearchBoost Price TargetBuy ➝ Buy$220.00 ➝ $225.00
8/9/2024ArgusUpgradeStrong-Buy
8/5/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$180.00 ➝ $200.00
7/25/2024BTIG ResearchInitiated CoverageBuy$220.00
5/8/2024HSBCLower Price TargetBuy ➝ Buy$230.00 ➝ $225.00
5/6/2024The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$223.00 ➝ $196.00
 

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here